Genticel
Records under this name other than the patents Genticel holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 7 of 7 · Back to Genticel
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,982,024 | CyaA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses Lapsed on the fee record Ended May 29, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 29, 2026 | From the USPTO record |
| US 8,628,779 | Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof Lapsed on the fee record Ended Jan 14, 2026 · High confidence | Lapsed on the fee record | Ended Jan 14, 2026 | High confidence |
| US 9,827,302 | HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders Lapsed on the fee record Ended Nov 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 28, 2025 | From the USPTO record |
| US 8,637,039 | Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof Term ended Term ended Sep 23, 2025 · From the USPTO record | Term ended | Term ended Sep 23, 2025 | From the USPTO record |
| US 9,387,243 | Recombinant Protein Carrying Human Papillomavirus Epitopes Inserted in an Adenylate Cyclase Protein or Fragment Thereof Therapeutic Uses Thereof Lapsed on the fee record Ended Jul 12, 2024 · Low confidence | Lapsed on the fee record | Ended Jul 12, 2024 | Low confidence |
| US 9,902,947 | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses Lapsed on the fee record Ended Feb 27, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 27, 2022 | From the USPTO record |
| US 9,486,524 | Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells Lapsed on the fee record Ended Nov 8, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 8, 2020 | From the USPTO record |